BL: Validity and completeness of the General Practice Research Database for studies of inﬂammatory bowel disease. Pharmacoepidemiol Drug Saf 11:211–218,
(2000). Ciproﬁbrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. Nutr Metab Cardiovasc Dis 10:1–6,
(2008). Connolly TM: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr Opin Investig Drugs 9:247–255,
(2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
(2004). Effects of gemﬁbrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes Obes Metab 4:187–194,
(2002). General Practice Research Database [online],
(2008). GoldﬁneAB:Assessingthecardiovascular safety of diabetes therapies.
(2000). Henke BR: The PPARs: from orphan receptorstodrugdiscovery.JMedChem43: 527–550,
(2007). Investigators: Effect of fenoﬁbrate on the need for laser treatment for diabeticretinopathy(FIELDstudy):arandomised controlled trial. Lancet 370: 1687–1697,
(2005). Investigators: Effects of long-term fenoﬁbrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861,
(2006). MotroM,BeharS:Attenuationofprogression of insulin resistance in patients with coronary artery disease by bezaﬁbrate. Arch Intern Med 166:737–741,
(2009). MR: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
(2004). Peroxisome proliferator-activated receptorligandbezaﬁbrateforpreventionof type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197–2202,
(2007). Prevention of type 2 diabetes: fact or ﬁction? Expert Opin Pharmacother 8:3147–3158,
(2000). Pta ´ckova ´ K, Dusinska ´ M: Effect of ciproﬁbrateonlipoproteinmetabolismandoxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
(2005). S: Effect of bezaﬁbrate on incidence of type 2 diabetes mellitus in obese patients.
(2005). Selling safety—lessons from muraglitazar.
(2003). SM: Effects of adding fenoﬁbrate (200 mg/ day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vessby B: A comparison between the effects of gemﬁbrozil and simvastatin on insulin sensitivity in patients with non-insulindependent diabetes mellitus and hyperlipoproteinemia.
(2003). YangCC,JickSS,TestaMA:Whoreceives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.
(2001). ZimmetP,AlbertiKG,ShawJ:Globaland societal implications of the diabetes epidemic.